Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

PID

- PMLiVE

Takeda shares long-term results for HyQvia in rare neurological disorder CIDP

The therapy is the first and only facilitated subcutaneous immunoglobulin treatment for CIDP

- PMLiVE

Takeda’s HyQvia receives MHRA approval for rare neurological disorder CIDP

The therapy offers patients with CIDP a typical dosing interval of four weeks

- PMLiVE

Takeda’s HyQvia receives EC approval for rare neuromuscular disorder CIDP

HyQvia can now be used as a maintenance therapy for patients of all ages with CIDP

- PMLiVE

Takeda’s HyQvia granted FDA approval to treat rare neuromuscular disorder CIDP

Approximately five to seven people per 100,000 in the US are affected by the disorder

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

Baxalta and CTI complete filing for Jakafi rival in US

Myelofibrosis candidate pacritinib aiming for accelerated approval

- PMLiVE

Baxter appoints Jose Almeida chairman and CEO

Will take over from Robert Parkinson Jr in Janary

Shire Basingstoke

Baxalta spells out opposition to Shire

Firm has rejected unsolicited $30bn bid from the Irish biopharma

- PMLiVE

Shire makes shock $30bn bid for Baxalta

Irish firm seeking to buy the newly spun-out biotech that used to be part of Baxter

- PMLiVE

Tantalising data for Baxter spin-off’s haemophilia therapy

Early-stage testing shows promise as a potentially transformative treatment

- PMLiVE

Baxalta will add $2.5bn in new product turnover by 2020

Pro forma sales expected to grow up to 8% between 2016 and 2020

- PMLiVE

2015 set to be a transitional year for Merck KGaA’s health unit

Weak pharma sales reported by the firm today

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links